veozah and breast cancer

Release time ：Dec-27,2024

Breast cancer is a prevalent malignant tumor with an increasing global incidence. Vezotuzumab, marketed as Veozah, is an innovative drug targeting breast cancer that inhibits cancer cell growth and spread by focusing on the HER2 protein. However, Veozah is not indicated for all breast cancer patients; it is beneficial primarily for those who test positive for HER2.

While utilizing Veozah for breast cancer treatment, patients may experience side effects such as nausea, vomiting, diarrhea, and rash, among others. Additionally, given that Veozah is a biologic agent, it is crucial to monitor patients' immune responses to prevent potential allergic reactions or other adverse effects. Despite these considerations, Veozah remains a potent treatment option for HER2-positive breast cancer patients, aiding in disease management and enhancing survival rates.

In general, although Veozah offers certain benefits in breast cancer treatment, patients must vigilantly monitor their health and use the medication responsibly under a physician's supervision. Moreover, patients should maintain healthy lifestyle practices, including smoking cessation, alcohol moderation, a balanced diet, and regular physical activity, to optimize treatment outcomes and minimize the risk of relapse.